A PK Study Comparing MB05, EU-sourced Synagis® and US-sourced Synagis® in Healthy Volunteers.

NCT05121246 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: MB05 (Proposed palivizumab biosimilar)
DRUG: EU-Synagis®
DRUG: US-Synagis®

Sponsor

mAbxience Research S.L.